STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1228 by analyst upside · 2026-06-27
STRO
Sutro Biopharma, Inc.
Healthcare · Market Cap $506M · P/E 0x
ANALYST PRICE TARGET
+58.3%
implied upside to consensus target
Current Price $30.52
Consensus Target $48.31
Bull Target $61.0
Bear Target $10.0
Analysts Covering 13
ANALYST CONSENSUS — BUY
Strong Buy
3
Buy
8
Hold
1
Sell
1
52-Week Low $6.7
52-Week High $43.85
YTD Return +178.5%
FUNDAMENTALS
Market Cap $506M
P/E Ratio (TTM) N/A
Forward P/E -4.4x
EPS (TTM) $-16.35
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $100M
Profit Margin -154.2%
52-WEEK RANGE
52-Week Low $6.7
52-Week High $43.85
Current Price $30.52
Bear Target $10.0
Bull Target $61.0
● Now $30.52 ● Target $48.31
TRADING DATA
Avg Volume 275K
YTD Return +178.5%
Analyst Count 13
Consensus Buy
Upside to Target +58.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Sutro Biopharma, Inc. (STRO) is currently trading at $30.52 with a Wall Street consensus price target of $48.31, implying potential upside of 58.3% over the next 12 months. 13 analysts currently cover STRO, with a consensus rating of Buy — 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $61.0, while the most cautious has a target of $10.0.

STRO operates in the Healthcare sector with a market capitalisation of $506M. The stock is up 178.5% year-to-date and is currently trading near the upper end of its 52-week range of $6.7 – $43.85.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for STRO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ● Initiated
Overweight 2026-05-28 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-05-15 29% win rate (7 calls)
Wedbush ↑ Upgrade
Neutral → Outperform 2026-05-15 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-15 31% win rate (48 calls)
Mizuho ● Initiated
Outperform 2026-04-30 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-23 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-17 Building track record
Leerink Partners ● Initiated
Outperform 2026-04-07 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →